Have your own idea? Try our Stock Screener
Taiwanese (TAIEX) Biotech Industry Analysis
UpdatedJan 02, 2026
DataAggregated Company Financials
Companies68
- 7D-1.3%
- 3M-2.4%
- 1Y0.2%
- YTDn/a
Over the last 7 days, the Biotech industry has dropped 1.3%, driven by a pullback from PharmaEssentia of 4.1%. In contrast, TaiGen Biopharmaceuticals Holdings has gained 11%. As for the longer term, the industry's performance has been flat for the past year. Earnings are forecast to grow by 41% annually.
Industry Valuation and Performance
Has the Taiwanese Biotech Industry valuation changed over the past few years?
| Date | Market Cap | Revenue | Earnings | PE | Absolute PE | PS |
|---|---|---|---|---|---|---|
| Fri, 02 Jan 2026 | NT$560.3b | NT$33.4b | -NT$6,808,544,000.00 | 30.1x | -82.3x | 16.8x |
| Sun, 30 Nov 2025 | NT$565.9b | NT$33.0b | -NT$7,467,266,000.00 | 39.7x | -75.8x | 17.1x |
| Tue, 28 Oct 2025 | NT$555.1b | NT$32.2b | -NT$8,364,979,000.00 | 35.2x | -66.4x | 17.2x |
| Thu, 25 Sep 2025 | NT$553.5b | NT$32.2b | -NT$8,364,979,000.00 | 37.8x | -66.2x | 17.2x |
| Sat, 23 Aug 2025 | NT$528.4b | NT$32.2b | -NT$8,215,909,000.00 | 33x | -64.3x | 16.4x |
| Mon, 21 Jul 2025 | NT$513.0b | NT$30.2b | -NT$6,412,141,000.00 | 36.9x | -80x | 17x |
| Wed, 18 Jun 2025 | NT$500.2b | NT$30.2b | -NT$6,460,452,000.00 | 37.8x | -77.4x | 16.5x |
| Fri, 16 May 2025 | NT$495.2b | NT$30.8b | -NT$6,244,132,000.00 | 32.9x | -79.3x | 16.1x |
| Sun, 13 Apr 2025 | NT$445.4b | NT$28.1b | -NT$7,302,014,000.00 | 27.7x | -61x | 15.8x |
| Tue, 11 Mar 2025 | NT$536.8b | NT$28.0b | -NT$8,407,141,000.00 | 34.1x | -63.9x | 19.2x |
| Thu, 06 Feb 2025 | NT$558.4b | NT$24.8b | -NT$10,902,841,000.00 | 38.3x | -51.2x | 22.5x |
| Sat, 04 Jan 2025 | NT$517.1b | NT$24.8b | -NT$10,902,841,000.00 | 35.4x | -47.4x | 20.9x |
| Mon, 02 Dec 2024 | NT$515.4b | NT$24.8b | -NT$10,782,551,000.00 | 38.6x | -47.8x | 20.8x |
| Wed, 30 Oct 2024 | NT$539.4b | NT$23.5b | -NT$10,829,095,000.00 | 40.2x | -49.8x | 23x |
| Fri, 27 Sep 2024 | NT$541.5b | NT$23.5b | -NT$10,829,095,000.00 | 34.7x | -50x | 23.1x |
| Sun, 25 Aug 2024 | NT$571.3b | NT$23.6b | -NT$10,755,142,000.00 | 34.4x | -53.1x | 24.3x |
| Tue, 23 Jul 2024 | NT$559.1b | NT$21.9b | -NT$11,110,643,000.00 | 41.6x | -50.3x | 25.5x |
| Thu, 20 Jun 2024 | NT$514.4b | NT$21.9b | -NT$11,110,643,000.00 | 42x | -46.3x | 23.5x |
| Sat, 18 May 2024 | NT$489.9b | NT$21.7b | -NT$11,182,688,000.00 | 43.2x | -43.8x | 22.5x |
| Mon, 15 Apr 2024 | NT$456.7b | NT$20.8b | -NT$12,061,940,000.00 | 50.8x | -37.9x | 21.9x |
| Wed, 13 Mar 2024 | NT$441.6b | NT$20.8b | -NT$9,880,735,000.00 | 39.2x | -44.7x | 21.3x |
| Fri, 09 Feb 2024 | NT$436.3b | NT$19.9b | -NT$9,857,794,000.00 | 40.5x | -44.3x | 21.9x |
| Sun, 07 Jan 2024 | NT$471.0b | NT$19.8b | -NT$9,748,146,000.00 | 39.3x | -48.3x | 23.8x |
| Tue, 05 Dec 2023 | NT$493.5b | NT$19.9b | -NT$9,737,975,000.00 | 42.5x | -50.7x | 24.8x |
| Thu, 02 Nov 2023 | NT$467.3b | NT$18.4b | -NT$10,823,013,000.00 | 50.4x | -43.2x | 25.3x |
| Sat, 30 Sep 2023 | NT$477.3b | NT$18.3b | -NT$10,774,226,000.00 | 43.3x | -44.3x | 26.1x |
| Mon, 28 Aug 2023 | NT$480.4b | NT$18.3b | -NT$10,598,878,000.00 | 42x | -45.3x | 26.2x |
| Wed, 26 Jul 2023 | NT$483.4b | NT$18.7b | -NT$10,724,655,000.00 | 45.7x | -45.1x | 25.9x |
| Fri, 23 Jun 2023 | NT$470.5b | NT$18.7b | -NT$10,709,428,000.00 | 42.6x | -43.9x | 25.2x |
| Sun, 21 May 2023 | NT$478.9b | NT$19.3b | -NT$9,957,876,000.00 | 42.5x | -48.1x | 24.9x |
| Tue, 18 Apr 2023 | NT$516.6b | NT$18.5b | -NT$9,609,324,000.00 | 42.8x | -53.8x | 27.9x |
| Thu, 16 Mar 2023 | NT$497.5b | NT$22.3b | -NT$7,407,579,000.00 | 36.9x | -67.2x | 22.3x |
| Sat, 11 Feb 2023 | NT$532.0b | NT$21.8b | -NT$7,778,690,000.00 | 38x | -68.4x | 24.4x |
| Mon, 09 Jan 2023 | NT$492.7b | NT$21.8b | -NT$7,778,690,000.00 | 35.9x | -63.3x | 22.6x |
Price to Earnings Ratio
-63.3x
Current Industry PE
- Investors are pessimistic on the Taiwanese Biotechs industry, indicating that they anticipate long term growth rates will be lower than they have historically.
- The 3-year average PS ratio of 21.9x is higher than the industry's current PS ratio of 16.8x.
Past Earnings Growth
- The earnings for companies in the Biotechs industry have improved over the last three years.
- Revenues for these companies have grown 15% per year.
- This means that more sales are being generated by these companies overall, and subsequently losses are decreasing too.
Industry Trends
Which industries have driven the changes within the Taiwanese Healthcare industry?
| TW Market | 2.14% | |
| Healthcare | -0.93% | |
| Biotech | -1.34% | |
| Biotech | -1.34% | |
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.
Top Stock Gainers and Losers
Which companies have driven the market over the last 7 days?
| Company | Last Price | 7D | 1Y | Valuation | |
|---|---|---|---|---|---|
| 6446 PharmaEssentia | NT$495.00 | 1.2% +NT$2.2b | -10.8% | PE38.1x | |
| 6550 Polaris Group | NT$31.60 | 4.8% +NT$1.1b | -30.9% | PS343.7x | |
| 4157 TaiGen Biopharmaceuticals Holdings | NT$13.10 | 9.6% +NT$818.6m | 15.9% | PS240.7x | |
| 4728 Sunmax Biotechnology | NT$402.00 | 3.1% +NT$653.6m | 44.6% | PE30.5x | |
| 7827 HanchorBio | NT$92.80 | 5.6% +NT$637.0m | n/a | PS38.6x |